1. Mohler, J.L., et al., The androgen axis in recurrent prostate cancer. Clin Cancer Res, 2004. 10(2): p. 440–8.
2. Attard, G., et al., Activity, toxicity, and effect on steroid precursor levels of abiraterone (A), an oral irreversible inhibitor of CYP17 (17α hydroxylase/17,20 lyase), in castrate men with castration refractory prostate cancer (CRPC). in Prostate Cancer Symposium. 2007. Orlando, Florida.
3. Ryan, C.J., et al., Phase I Evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings, 2007. 25(18S): p. 5064.
4. Lin, A.M., et al., A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int, 2006. 98(4): p. 763–9.
5. Collette, L., Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol, 2008. 53(1): p. 941–9.